

High levels of long non-coding RNA DICER1-AS1 are associated with poor clinical prognosis in patients with osteosarcoma

X.-H. HU, J. DAI, H.-L. SHANG, Z.-X. ZHAO, Y.-D. HAO

Department of Orthopedics, The Affiliated Huaian No. 1 People's Hospital, Nanjing Medical University, Huai'an, Jiangsu, China

Abstract. – **OBJECTIVE:** Long noncoding RNA DICER1-AS1 (DICER1-AS1) has been reported to be upregulated in osteosarcoma cells and to serve as a tumor promoter. However, the clinical significance of DICER1-AS1 in osteosarcoma remains unclear. The aim of this study was to investigate the association of DICER1-AS1 expression with prognosis of osteosarcoma.

PATIENTS AND METHODS: The expression of DICER1-AS1 was measured in 214 osteosarcoma samples and normal bone samples by using Real-time PCR. The correlations between DICER1-AS1 expression and clinical features were statistically analyzed. Overall survival (OS), disease-free survival (DFS) were examined using Kaplan-Meier curves. Multivariate analysis was performed to analyze the prognostic significance of DICER1-AS1 expression.

RESULTS: It was found that the expression levels of DICER1-AS1 in osteosarcoma tissues were significantly higher than those in corresponding noncancerous bone tissues ($p < 0.01$). Higher DICER1-AS1 had a significant association with clinical stage ($p = 0.005$), distant metastasis ($p = 0.000$). Kaplan-Meier survival analysis showed that patients with high DICER1-AS1 expression had a significantly lower OS and DFS compared with the low DICER1-AS1 expression group ($p = 0.007$ and $p = 0.0001$). In multivariate Cox model, our results showed that DICER1-AS1 expression was an independent poor prognostic factor for both 3-year OS (HR = 3.236, 95% CI: 1.148-5.323; $p = 0.001$) and 5-year DFS (HR = 3.935, 95% CI: 1.549-9.349; $p = 0.001$).

CONCLUSIONS: DICER1-AS1 is up-regulated in osteosarcoma and may serve as a potential prognostic biomarker for osteosarcoma.

Key words:

DICER1-AS1, Osteosarcoma, Prognosis.

Introduction

Osteosarcoma is a debilitating, high-grade primary bone malignancy affecting rapidly

growing bone and is responsible for 20% of all primary bone sarcomas^{1,2}. Osteosarcoma is the most frequent primary bone malignant tumor and is often identified in children between the ages of 10 and 20 years³. With the advancement of multiple therapeutic strategies for osteosarcoma, including surgical resection, adjuvant chemotherapy and radiotherapy, the 5-year survival rate of osteosarcoma patients has been dramatically improved⁴. However, the prognosis of osteosarcoma patients with metastases is rather poor, and the long-term survival rate is only 10-15%. Therefore, examining the pathogenesis and biological features of osteosarcoma is crucial to enhance early detection and treatment. In the human genome, approximately 2% of transcripts can be translated into proteins, whereas 98% of transcripts are noncoding RNAs (ncRNAs)⁵. Long noncoding RNA (lncRNA), >200 nucleotides in length, is a member of the non-coding RNA family that can regulate gene expression in transcriptional or posttranscriptional level⁶. Growing studies⁹⁻¹¹ show that lncRNAs could control various cellular processes, including proliferation, differentiation, apoptosis and metastasis, and are implicated in human diseases. More importantly, emerging evidence indicates that lncRNAs may play complex and extensive roles in promoting the tumorigenesis and progression of tumors^{12,13}. In addition, aberrantly expressed lncRNAs can be detected in tumor tissues, and their expression profiles are different in different types of tumor. These findings indicate lncRNAs as suitable biomarkers to be used for osteosarcoma diagnosis and prognosis^{14,15}. Recently, lncRNA DICER1-AS1 (DICER1-AS1), a novel tumor-related lncRNA, was reported to be abnormally expressed in osteosarcoma cells by lncRNA microarray and RT-PCR. Further cells experiments showed that

DICER1-AS1 may function as a tumor promoter in osteosarcoma progression¹⁶. Up to date, this is the only study on the expression and biological function of DICER1-AS1 in tumor. However, whether DICER1-AS1 expression was dysregulated in osteosarcoma tissues and its clinical significance in osteosarcoma patients, remain largely unknown. Our present aimed to detect DICER1-AS1 expression in osteosarcoma patients and its potential as a prognostic biomarker for osteosarcoma patients.

Patients and Methods

Patients

A total of 214 clinical samples were obtained from patients with osteosarcoma and paired adjacent nontumor bone tissue at The Affiliated Huaian No.1 People's Hospital of Nanjing Medical University. All specimens were snap frozen in liquid nitrogen immediately after surgery and stored at -80°C. None of the patients had previously received radiotherapy, chemotherapy, or immunotherapy. The stage of the disease was classified according to the pathological tumor-node-metastasis staging system. The follow-up information of all the participants was updated every 3 months for 5 years. This study was approved by the Research Ethics Committee of The Affiliated Huaian No.1 People's Hospital of Nanjing Medical University. Written informed consent was obtained from all of the

RNA Extraction and RT-PCR

Total RNA was extracted with the TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's instructions. cDNA was reverse transcribed using QuantiTect Reverse Transcription Kit (Qiagen, Crawley, UK). Quantitative reverse transcription polymerase chain reaction (RT-PCR) was conducted using a SYBR Green Ex Taq II Kit (Thermo Fisher Scientific, Waltham, MA, USA) on an Applied Biosystems 7500 Real-Time PCR system (Thermo Fisher Scientific, Waltham, MA, USA). The relative levels of DICER1-AS1 were normalized

to the expression of U6 by the $2^{-\Delta\Delta Ct}$ method. The primers used in this study were synthesized by GenePharma Company (Xuhui, Shanghai, China) and the sequences were shown in Table 1.

Statistical Analysis

All data were analyzed SPSS using the software package (SPSS Inc., Chicago, USA). Data were analyzed using independent *t*-test. The paired-sample *t*-test was used for analysis of differential DICER1-AS1 expression between tumor and normal tissues. Associations between clinicopathological parameters and DICER1-AS1 expression were evaluated using chi-square tests. Overall survival (OS) and disease-free survival (DFS) were estimated using the Kaplan-Meier method. The significance of survival variables was evaluated using a multivariate proportional hazards regression analysis. A *p*-value < 0.05 is considered statistically significant.

Results

Increased Expression of DICER1-AS1 in Osteosarcoma Tissues

To reveal the role of DICER1-AS1 in progression of osteosarcoma, we performed the qRT-PCR to evaluate the expression of DICER1-AS1 in 214 osteosarcoma and corresponding non-tumor tissues. We found that relative expression of DICER1-AS1 normalized to U6 in renal cancer was found to be 3.89 ± 0.47 , while that in matching adjacent normal specimens was 7.67 ± 0.93 . Statistical results indicated that DICER1-AS1 expression was upregulated in osteosarcoma tissues compared with normal tissues (*p* < 0.01, Figure 1).

Correlation of DICER1-AS1 Expression with Clinicopathological Features

To investigate the relationship between DICER1-AS1 expression and clinical features in osteosarcoma, all osteosarcoma patients were classified into two groups depending on DICER1-AS1 levels in tumor tissues relative to the median

Table 1. Primer sets used in the present study.

Gene names	Forward (5'-3')	Reverse (5'-3')	Application
DICER1-AS1	TGACCAGTCTACCCCTCCT	CTGAAGCACCTGAAATGCG	Real-time RT-PCR
U6	ACCCTGAGAAATACCCTCACAT	GACGACTGAGCCCCTGATG	Real-time RT-PCR




Figure 1. Expression of DICER1-AS1 in osteosarcoma tissues and matched normal bone tissues. DICER1-AS1 expression was significantly higher in osteosarcoma tissues than in the matched normal bone tissues ($p < 0.01$).

ratio: high DICER1-AS1 expression group ($n = 110$) and low DICER1-AS1 expression group ($n = 104$). As shown in Table II, it was observed that DICER1-AS1 expression was closely associated with clinical stage ($p = 0.005$) and distant metastasis ($p = 0.000$). However, there were no significant relationships between DICER1-AS1 expression and other clinicopathological parameters, including age, gender, tumor size, anatomic location and response to chemotherapy (all $p > 0.05$).

Association of DICER1-AS1 Expression with Prognosis of Osteosarcoma Patients

In order to further explore the prognostic value of DICER1-AS1 expression in osteosarcoma patients, survival curves were constructed by Kaplan-Meier method and compared by the log-rank test. As shown in Figure 2, osteosarcoma patients with higher DICER1-AS1 expression level had shorter OS than those with high DICER1-AS1 expression level ($p = 0.007$). Similarly, we also found that DICER1-AS1 expression was significantly correlated with osteosarcoma patients' DFS ($p < 0.0001$, Figure 3). In multivariate analysis using the Cox proportional hazards model, we further found that DICER1-AS1 expression ($p = 0.004$ and $p = 0.002$, respectively), clinical stage ($p = 0.015$ and $p = 0.004$, respectively) and distant metastasis ($p = 0.006$ and $p = 0.01$, respectively) were independent prognostic factors for both OS and DFS in osteosarcoma patients (Table III).

Discussion

Despite advances in therapeutic strategies, the outcome remains poor for most osteosarcoma patients, especially those with metastatic or recurrent osteosarcoma. Therefore, understanding the mechanisms underlying osteosarcoma pathogenesis may help yield novel biomarkers for early detection, prog-

Table II. Association of DICER1-AS1 expression with clinicopathologic features of osteosarcoma.

Clinicopathologic features	No. of cases	DICER1-AS1 expression		<i>p</i> -value
		High	Low	
Age (y)				0.565
< 25	106	48	52	
≥ 25	114	62	52	
Gender				NS
Male	136	70	66	
Female	78	40	38	
Tumor size (cm)				NS
< 8	106	60	46	
≥ 8	108	50	58	
Anatomic location				NS
Diaphysis/femoral head	135	65	70	
Other	79	45	34	
Response to chemotherapy				NS
Complete	116	55	61	
Partial	98	55	43	
Clinical stage				0.005
IA	134	59	75	
III	80	51	29	
Distant metastasis				0.000
Absent	145	64	81	
Present	69	46	23	




Figure 2. Kaplan-Meier postoperative survival curve for patterns of patients with osteosarcoma. Osteosarcoma patients with high DICER1-AS1 expression showed shorter overall survival time than those with low DICER1-AS1 expression ($p = 0.0007$).




Figure 3. Kaplan-Meier postoperative survival curve for patterns of patients with osteosarcoma. Osteosarcoma patients with high DICER1-AS1 expression showed shorter disease-free survival time than those with low DICER1-AS1 expression ($p < 0.0001$).

nosis and treatment^{17,18}. Numerous studies¹⁹⁻²¹ have demonstrated that several lncRNAs, such as lncRNA TP73-AS1, lncRNA ZFAS1, lncRNA XIST, may serve as a diagnostic and prognostic marker in various tumors, including osteosarcoma. In the present study, our data indicated that DICER1-AS1 was important for osteosarcoma initiation and progression and held promise as a prognostic biomarker to predict survival in osteosarcoma. Emerging studies have confirmed that lncRNAs are involved in cell proliferation, apoptosis, invasion and metastasis in various types of cancers, including osteosarcoma²². For instance, Zhang et al²³ reported that lncRNA HOXA11-AS1 was highly expressed in osteosarcoma tissues and cell lines and associated with the prognosis of osteosarcoma patients, and its low expression promoted doxorubicin resistance in osteosarcoma by modulating HOXA11 expression. Cui et al²⁴ found that the expression of lncRNA HOXA11-AS was significantly up-regulated in osteosarco-

ma patients and associated with advanced clinical stage, distant metastasis and poor overall survival in osteosarcoma. Further gain- and lost-of-function assay showed that HOXA11-AS served as a tumor suppressor by sponging miR-124-3p in osteosarcoma. Wen et al²⁵ reported that lncRNA HUCA1 have the potential to be a promising biomarker for discriminating patients with osteosarcoma from healthy controls and predicting the prognosis of osteosarcoma patients. Recently, Gu et al¹⁶ firstly reported DICER1-AS1 as a up-regulated lncRNA in osteosarcoma cells. Then, they performed *in vivo* and *in vitro* assay, finding that knockdown of DICER1-AS1 significantly suppressed the proliferation, invasion and autophagy of osteosarcoma cells via miR-30b/ATG5. However, whether DICER1-AS1 was up-regulated in clinical osteosarcoma tissues, and its prognostic value have not been investigated. In this study, based on the results of DICER1-AS1 expression in osteosarcoma cells, we firstly performed

Table 1. Multivariate survival analysis of overall survival and disease-free survival in 214 osteosarcoma patients.

Variable	Overall survival			Disease-free survival		
	RR	95% CI	<i>p</i>	RR	95% CI	<i>p</i>
Age	1.562	0.782-2.233	0.415	1.493	0.944-2.039	0.327
Gender	1.836	0.559-2.672	0.232	1.553	0.739-2.328	2.118
Tumor size	2.214	0.932-2.873	0.118	1.884	0.582-2.449	0.217
Anatomic location	1.664	0.873-2.326	0.177	1.885	0.942-2.683	0.114
Response to chemotherapy	1.347	0.739-2.215	0.114	1.573	0.949-2.443	0.134
Clinical stage	3.149	1.033-4.237	0.015	3.673	1.235-5.623	0.004
Distant metastasis	3.136	1.235-5.028	0.006	4.237	1.663-6.238	0.001
DICER1-AS1 expression	3.236	1.148-5.347	0.004	3.935	1.556-6.349	0.001

RT-PCR to detect the levels of DICER1-AS1 in osteosarcoma patients. Consistent with previous study, our results also confirmed DICER1-AS1 as an up-regulated lncRNA in osteosarcoma patients. Subsequently, clinical assay revealed that DICER1-AS1 expression was closely associated with clinical stage and distant metastasis, indicating that DICER1-AS1 may contribute to malignant tumor. Moreover, based on Kaplan-Meier survival analysis, we demonstrated that higher DICER1-AS1 expression was associated with poorer DFS and OS, when compared to lower DICER1-AS1 expression. Most importantly, multivariate analysis revealed that DICER1-AS1 could be used as an independent prognostic factor for both OS and DFS in osteosarcoma patients. Our finding, for the first time, indicated the possibility of using high expression levels of ICER1-AS1 as a predictor for prognosis and survival. However, to be honest, one limitation of the current study is that there was relatively small sample size enrolled. Thus, larger sample size will be needed to further demonstrate our findings.

Conclusions

We suggest that high levels of DICER1-AS1 might reflect a less aggressive osteosarcoma phenotype and predict better survival for patients with osteosarcoma. DICER1-AS1 expression may be a useful prognostic marker for this disease.

Conflict of Interest

The Authors declare they have no conflict of interests.

References

- 1) GEMMANI G, SINGH N. The epidemiology of osteosarcoma. *Cancer Treat Res* 2009; 152: 3-13.
- 2) LEBLANC R, MILLER CL, MYERS DE, DASS CR, CHODURA J. The molecular pathogenesis of osteosarcoma. *Dev Dis Rev* 2011; 2011: 959248.
- 3) MARTELLO M, JONES RJ, SAVAGE SA. Osteosarcoma incidence and survival rates from 1973 to 2004: data from the surveillance, epidemiology, and end results program. *Cancer* 2009; 115: 1531-1543.
- 4) GILL J, AHLUWALIA MK, GELLER D, GORLICK R. New targets and approaches in osteosarcoma. *Pharmacol Ther* 2013; 137: 89-99.
- 5) POTTER SM, NERI D, FUCHS B. Recent advances in osteosarcoma. *Curr Opin Pharmacol* 2014; 16: 15-23.
- 6) ANDERSON ME. Update on survival in osteosarcoma. *Orthop Clin North Am* 2016; 47: 283-292.
- 7) KENTWELL J, GUNDARA JS, SIDHU SB. Noncoding RNAs in endocrine malignancy. *Oncologist* 2012; 17: 483-491.
- 8) SPIZZO R, ALMEIDA MI, COLOMBATTI A, GALLI GA. Long noncoding RNAs and cancer: a new frontier of translational research? *Oncotarget* 2012; 31: 4577-4587.
- 9) NAGANO T, FRASER P. Non-coding full-length for long noncoding RNAs. *Nat Rev* 2011; 145: 178-188.
- 10) UCHIDA S, DIMMELER S. Long noncoding RNAs in cardiovascular disease. *Circ Res* 2015; 116: 737-750.
- 11) BATISTA PJ, CHEN HY. Long noncoding RNAs: cellular address codes in development and disease. *Cell* 2014; 157: 1298-1307.
- 12) CHEETHAM JW, GUNTER M, MATTICK JS, LINGER ME. Long noncoding RNAs: the genetics of cancer. *Br J Cancer* 2013; 108: 214-225.
- 13) ZHANG M, WU WB, WANG W, WANG XH. LncRNA NEAT1 is closely related with progression of breast cancer via promoting proliferation and EMT. *Eur Rev Med Pharmacol Sci* 2017; 21: 1020-1026.
- 14) LIU N, LIU X, SHI K. Circulating long non-coding RNA TP73-AS1 is a potential diagnostic biomarker for non-small cell lung cancer. *Clin Chim Acta* 2017; 475: 152-156.
- 15) ZHOU LH, LI J, CHEN Y, JIANG XW, OUYANG YR, LIU Y, ZHONG H, LI H, XIAO T. Microarray expression profile of long noncoding RNAs in human osteosarcoma. *Biochem Biophys Res Commun* 2013; 433: 200-206.
- 16) GU Z, HOU Z, ZHENG L, WANG X, WU L, ZHANG C. LncRNA DICER1-AS1 promotes the proliferation, invasion and autophagy of osteosarcoma cells via miR-30b/ATG5. *Biomed Pharmacother* 2018; 104: 110-118.
- 17) FERRARI S, SERRA M. An update on chemotherapy for osteosarcoma. *Expert Opin Pharmacother* 2015; 16: 2727-2736.
- 18) REN L, KHANNA C. Role of ezrin in osteosarcoma metastasis. *Adv Exp Med Biol* 2014; 804: 181-201.
- 19) ZHANG L, FANG F, HE X. Long noncoding RNA TP73-AS1 promotes non-small cell lung cancer progression by competitively sponging miR-449a/EZH2. *Biomed Pharmacother* 2018; 104: 705-711.
- 20) NIE F, YU X, HUANG M, WANG Y, XIE M, MA H, WANG Z, DE W, SUN M. Long noncoding RNA ZFAS1 promotes gastric cancer cells proliferation by epigenetically repressing KLF2 and NKD2 expression. *Oncotarget* 2017; 8: 38227-38238.
- 21) LI GL, WU YX, LI YM, LI J. High expression of long non-coding RNA XIST in osteosarcoma is associated with cell proliferation and poor prognosis. *Eur Rev Med Pharmacol Sci* 2017; 21: 2829-2834.

- 22) FATICA A, BOZZONI I. Long non-coding RNAs: new players in cell differentiation and development. *Nat Rev Genet* 2014; 15: 7-21.
- 23) ZHANG CL, ZHU KP, MA XL. Antisense lncRNA FOXC2-AS1 promotes doxorubicin resistance in osteosarcoma by increasing the expression of FOXC2. *Cancer Lett* 2017; 396: 66-75.
- 24) CUI M, WANG J, LI Q, ZHANG J, JIA J, ZHAN X. Long non-coding RNA HOXA11-AS functions as a competing endogenous RNA to regulate ROCK1 expression by sponging miR-124-3p in osteosarcoma. *Biomed Pharmacother* 2017; 92: 437-444.
- 25) WEN JJ, MA YD, YANG GS, WANG GM. Circulating long non-coding RNA lncRNA-1 as potential biomarkers for diagnosis and prognosis of osteosarcoma. *Eur Rev Med Pharmacol Sci* 2017; 21: 498-503.

RETRACTED